Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAP2 | P11137 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954980 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2227263 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Benzene SCHEMBL28244199 | 0.82 | MEN1 (0.58) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1253813 | 0.80 | EGFR (0.50) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2800262 | 0.80 | KDM4E (0.57) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL7387632 | 0.78 | RAB9A (0.49) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL31025899 | 0.77 | ALOX15 (0.65) | KDM4EHPGDMEN1KMT2A | |
| SCHEMBL29954951 | 0.77 | MEN1 (0.58) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL29955514 | 0.77 | RXFP1 (0.58) | KDM4EALDH1A1MEN1KMT2APOLB | |
| SCHEMBL29954193 | 0.77 | MAP2 (0.49) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10195049-A | — | — | None | — | — | JP | disclosed |
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024162746-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | 한국화학연구원 | 2024-08-08 | — | — | WO | disclosed |
| WO-2021143816-A1 | FUSED IMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-7429578-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| US-6977298-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | Agouron Pharmacetucals, Inc. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1140936-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | WEBBER STEPHEN EVAN (US) | 2003-04-24 | — | — | US | disclosed |
| US-6495541-B1 | POTENTIATION OF ANTICANCER THERAPIES AND INHIBITION OF NEUROTOXICITY CONSEQUENT TO STROKE, HEAD TRAUMA, AND NEURO-DEGENERATIVE DISEASES; SUCH AS 2-BROMO-3,4-DIHYDROPYRROLO-(4,3,2-DE)ISOGUINOLIN-5-ONE | AGOURON PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| CN-1351590-A | Compound (I) | ASTRAZENECA OK LTD (SE) | 2002-05-29 | — | — | CN | disclosed |
| EP-1140936-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| CN-1265591-A | Coumpound | ZENECA LTD (GB) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000042040-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| JP-H10195049-A | INDOLE-2-CARBOXYLIC ESTER DERIVATIVE AND MICROBICIDE FOR HORTICULTURE INCLUDING THE DERIVATIVE AS ACTIVE INGREDIENT | OTSUKA CHEM CO LTD | 1998-07-28 | — | — | JP | disclosed |
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5137910-A | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | C.D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | KDM4E 3048/4885ALDH1A1 901/4885HPGD 465/4885 |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | KDM4E 3048/4885ALDH1A1 901/4885HPGD 465/4885 |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP11, PARP2 | KDM4E 3192/4885ALDH1A1 608/4885HPGD 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.